Look for:

Our offer for

GLAXOSMITHKLINE ORD GBP0.25


ISIN:
GB0009252882
WKN:
0925288

2021/11/29 12:02:43
Price
1,518.9903 GBp
Difference 0.54% (8.19)

General attributes

ISINGB0009252882
SymbolGSK
ExchangeLondon Stock Exchange
CurrencyGBp
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)89,120 EUR
BenchmarkFTSE 100

Market data

Bid (Bid size)1,518.80 GBp (240)
Ask (Ask size)1,519.00 GBp (500)
Open1,515.60 GBp
High1,526.40 GBp
Low1,505.40 GBp
Close (prev. day)1,510.80 GBp
VWAP1,516.324691 GBp
Volume (pcs)2,118,419
Trading volume3,212,211,036.00
Number of trades7,171
Last size9

Futures and Options

Related Futures38
Related Options-

PDF Downloads

Company report: GLAXOSMITHKLINE ORD GBP0.25PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2021/11/29 12:02:43
Price
1,518.9903 GBp
Difference 0.54% (8.19)

General attributes

ISINGB0009252882
SymbolGSK
ExchangeLondon Stock Exchange
CurrencyGBp
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)89,120 EUR
BenchmarkFTSE 100

Market data

Bid (Bid size)1,518.80 GBp (240)
Ask (Ask size)1,519.00 GBp (500)
Open1,515.60 GBp
High1,526.40 GBp
Low1,505.40 GBp
Close (prev. day)1,510.80 GBp
VWAP1,516.324691 GBp
Volume (pcs)2,118,419
Trading volume3,212,211,036.00
Number of trades7,171
Last size9

Performance and Risk

6m1Y3Y
Perf (%)+11.65%+8.69%-4.04%
Perf (abs.)+157.60+120.80-63.60
Beta0.520.640.66
Volatility14.7917.7522.46
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)1,530.0000 GBp (4,785,822)
Ø price 30 days | Ø volume 30 days (pcs.)1,515.2067 GBp (6,746,993)
Ø price 100 days | Ø volume 100 days (pcs.)1,457.5540 GBp (5,845,511)
Ø price 250 days | Ø volume 250 days (pcs.)1,387.5984 GBp (6,844,192)
YTD High | date1,604.4000 GBp (2021/11/12)
YTD Low | date1,190.8000 GBp (2021/02/26)
52 Weeks High | date1,604.4000 GBp (2021/11/12)
52 Weeks Low | date1,190.8000 GBp (2021/02/26)

All listings for GLAXOSMITHKLINE ORD GBP0.25

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Xetra2021/11/2911:5918.22 EUR0.5772
Tradegate2021/11/2912:0018.20 EUR0.3451
Stuttgart2021/11/2910:3618.04 EUR0.016
SIX Swiss Exchange2020/04/2117:3621.50 CHF0.001
Munich2021/11/2909:1018.20 EUR0.002
London Stock Exchange2021/11/2912:021,519.00 GBp3,212.977,173
Hanover2021/11/2908:0217.84 EUR0.001
Hamburg2021/11/2908:2418.02 EUR0.001
Frankfurt2021/11/2911:0418.12 EUR0.035
FINRA other OTC Issues2021/11/2618:5720.13 USD0.024
Duesseldorf2021/11/2912:0018.18 EUR0.005
Berlin2021/11/2909:3918.26 EUR0.022

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=2549&ID_TYPE_IMAGE_LOGO=2

Contact Details

GLAXOSMITHKLINE PLC
- -
980 Great West Road - TW8 9GS Middlesex
Telefon: 44-20-8047-5000
Fax: 44-20-8047-7807
E-mail: -

PDF Downloads

Company report: GLAXOSMITHKLINE ORD GBP0.25PDF Download

Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Members of Management Board

Emma WalmsleyChairman of Managing Board
Hal BarronMember of Executive Committee
Brian McNamaraMember of Executive Committee
David RedfernMember of Executive Committee
Deborah WaterhouseMember of Executive Committee
Diana ConradMember of Executive Committee
Iain MackayMember of Executive Committee
James FordMember of Executive Committee
Karenann TerrellMember of Executive Committee
Luke MielsMember of Executive Committee
Phil ThomsonMember of Executive Committee
Regis SimardMember of Executive Committee
Roger ConnorMember of Executive Committee
Sally JacksonMember of Executive Committee

Board of directors

Jonathan SymondsChairman of Supervisory Board
Anne BealMember of Supervisory Board
Hal BarronMember of Supervisory Board
Jesse GoodmanMember of Supervisory Board
Laurie GlimcherMember of Supervisory Board
Charles BancroftMember of Supervisory Board
Iain MackayMember of Supervisory Board
Lauren FlanaganMember of Supervisory Board
Lynn ElsenhansMember of Supervisory Board
Manvinder Singh BangaMember of Supervisory Board
Urs RohnerMember of Supervisory Board
Vivienne CoxMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. For more details please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer